作者
Isotta Landi, Deepak A Kaji, Liam Cotter, Tielman Van Vleck, Gillian Belbin, Michael Preuss, Ruth JF Loos, Eimear Kenny, Benjamin S Glicksberg, Noam D Beckmann, Paul O’Reilly, Eric E Schadt, Eric D Achtyes, Peter F Buckley, Douglas Lehrer, Dolores P Malaspina, Steven A McCarroll, Mark H Rapaport, Ayman H Fanous, Michele T Pato, Carlos N Pato, Tim B Bigdeli, Girish N Nadkarni, Alexander W Charney
发表日期
2021/9
期刊
Nature medicine
卷号
27
期号
9
页码范围
1576-1581
出版商
Nature Publishing Group US
简介
Polygenic risk scores (PRS) summarize genetic liability to a disease at the individual level, and the aim is to use them as biomarkers of disease and poor outcomes in real-world clinical practice. To date, few studies have assessed the prognostic value of PRS relative to standards of care. Schizophrenia (SCZ), the archetypal psychotic illness, is an ideal test case for this because the predictive power of the SCZ PRS exceeds that of most other common diseases. Here, we analyzed clinical and genetic data from two multi-ethnic cohorts totaling 8,541 adults with SCZ and related psychotic disorders, to assess whether the SCZ PRS improves the prediction of poor outcomes relative to clinical features captured in a standard psychiatric interview. For all outcomes investigated, the SCZ PRS did not improve the performance of predictive models, an observation that was generally robust to divergent case ascertainment …
引用总数
学术搜索中的文章
I Landi, DA Kaji, L Cotter, T Van Vleck, G Belbin… - Nature medicine, 2021